Introduction & Objective: Obesity is characterized by an increase of fat mass and a reduced muscle mass. Sarcopenia is diagnosed based on low muscle strength, quantity, and physical performance. Muscle is the main peripheral glucose metabolizer and insulin resistance induces muscle mass lost. Sarcopenic Obesity (SO) may be defined as a clinical and functional condition characterized by the coexistence of obesity and sarcopenia. SO is associated with a poor prognosis in chronic diseases and poor metabolic control. We aimed to assess the relationship between SO and both, metabolic control and comorbidities in T2DM inpatients.
Methods: Over 1300 inpatients, we analyzed 376 with screening (SARC-F: strength; walking assistance; rising from a chair; climbing stairs) for sarcopenia. We compared patients with and without sarcopenia (SARC-F <u>></u>4).
Results: 243 patients had sarcopenia. In table 1 we show the main characteristics of the groups. In the unadjusted logistic regression model, the risk of mortality among sarcopenics was OR 3.67 (95% CI, 1.22-15.85), p=0.039; After adjustment, the risk of mortality is related to age (p=0.001), comorbidity (p=0.02) and frailty (p=0.04).
Conclusion: patients with SO were older and had greater frailty and comorbidities. They had more glycemic variability and poor prognosis which depends on their own characteristics.
J. Carretero Gomez: None. J. Ena: None. F. Carrasco-Sánchez: None. J. Arevalo Lorido: None. L. Garcia Martinez: None. P. González González: None.
